U.S. Markets open in 1 hr 20 mins
  • S&P Futures

    3,602.50
    +26.50 (+0.74%)
     
  • Dow Futures

    29,850.00
    +304.00 (+1.03%)
     
  • Nasdaq Futures

    11,939.25
    +34.00 (+0.29%)
     
  • Russell 2000 Futures

    1,841.30
    +24.20 (+1.33%)
     
  • Crude Oil

    43.65
    +0.59 (+1.37%)
     
  • Gold

    1,807.60
    -30.20 (-1.64%)
     
  • Silver

    23.12
    -0.51 (-2.15%)
     
  • EUR/USD

    1.1869
    +0.0024 (+0.2018%)
     
  • 10-Yr Bond

    0.8570
    0.0000 (0.00%)
     
  • Vix

    22.00
    -1.70 (-7.17%)
     
  • GBP/USD

    1.3328
    +0.0006 (+0.0413%)
     
  • USD/JPY

    104.5500
    +0.0620 (+0.0593%)
     
  • BTC-USD

    19,192.08
    +740.12 (+4.01%)
     
  • CMC Crypto 200

    377.91
    +16.48 (+4.56%)
     
  • FTSE 100

    6,409.25
    +75.41 (+1.19%)
     
  • Nikkei 225

    26,165.59
    +638.22 (+2.50%)
     

Recap: DexCom Q3 Earnings

Benzinga Insights
·1 min read

Shares of DexCom (NASDAQ:DXCM) rose 1.15% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 44.62% over the past year to $0.94, which beat the estimate of $0.64.

Revenue of $500,900,000 up by 26.39% from the same period last year, which beat the estimate of $476,750,000.

Outlook

DexCom hasn't issued any earnings guidance for the time being.

The upcoming fiscal year's revenue expected to be between $1,900,000,000 and $1,900,000,000.

Details Of The Call

Date: Oct 27, 2020

View more earnings on DXCM

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/ctub67qk

Price Action

Company's 52-week high was at $456.23

Company's 52-week low was at $145.23

Price action over last quarter: down 10.66%

Company Description

Dexcom designs and commercializes continuous glucose monitoring (CGM) systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company sells three different pieces of equipment, a sensor, a transmitter, and a receiver.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.